LifeStance Health Group, Inc. (LFST): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
LifeStance Health Group, Inc. (LFST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001845257 0001845257 2026-07-02 2026-07-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2
How this was made
The 30-second read
Why it matters
The resignation of Jeffrey Rhodes and appointment of Thurman Justice, Lori Goltermann, and Safwan Shabab updates board composition and committee membership; RSU awards were granted under the 2021 Equity Incentive Plan.
Market read
This is a governance/compensation disclosure that may slightly affect perceived oversight quality but lacks new financial or strategic catalysts.
What to watch
Committee assignments (audit/quality & compliance/compensation & nominating) could matter if the company is concurrently addressing compliance or internal-control issues, but the filing provides no such context.
Background
The company filed an SEC Form 8-K (Item 5.02) on July 7, 2026 covering director/officer changes and compensatory arrangements.
Ticker impact
LifeStance disclosed a board resignation (Jeffrey Rhodes) and appointment of three new directors, plus initial RSU grants under its equity plan.
Likely modest, short-lived reaction unless paired with additional guidance, investigations, or strategic actions not included here.
The filing is an SEC 8-K Item 5.02 describing governance changes and RSU awards; it does not include financial results, strategy shifts, or regulatory/legal developments.
Market effects
Minimal read-through to the behavioral health/healthcare services sector because the disclosure is governance/committee related without operational metrics.
None indicated; company-specific board changes only.
None indicated; no cross-border deal, regulation, or supply-chain impact described.
Counterpoint
Director turnover can sometimes precede broader strategic or financial actions; traders may watch for follow-on 8-Ks (e.g., CEO/CFO changes, restructuring, or guidance) not present in this filing.
Key entities
- issuerLifeStance Health Group, Inc.
Nasdaq-listed behavioral healthcare provider filing the 8-K Item 5.02.
- directorJeffrey Rhodes
Resigned from the board and all committees effective immediately on July 2, 2026.
- directorThurman Justice
Appointed Class II director; serves on audit and quality/compliance committees; received initial RSUs.
- directorLori Goltermann
Appointed Class II director; serves on compensation and nominating/governance committees; received initial RSUs.
- directorSafwan Shabab
Appointed Class III director; serves on nominating and governance committee; appointed under a stockholder’s agreement.
